Leveraging DNA repair deficiency in gynecologic oncology

被引：1

作者：

Walsh, Christine S. ^{[1
]}

Hodeib, Melissa ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, 8700 Beverly Blvd,Suite 160W, Los Angeles, CA 90048 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2016年 / 28卷 / 01期

关键词：

BRCA1/2; homologous recombination; ovarian cancer; poly (ADP-ribose) polymerase inhibitor; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; CANCER SUSCEPTIBILITY GENE; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; FALLOPIAN-TUBE; BREAST-CANCER; PRIMARY PERITONEAL; CELLULAR-RESPONSE; SEROUS OVARIAN;

D O I：

10.1097/GCO.0000000000000236

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Purpose of review The review discusses DNA repair deficiencies in ovarian cancer and how this has become the target for poly (ADP-ribose) polymerase (PARP) inhibition as a successful therapeutic strategy. Recent findings Hereditary ovarian cancers arise from germline mutations in BRCA1, BRCA2, or other important genes in the DNA repair process of homologous recombination. Sporadic ovarian cancers can also acquire a phenotype of homologous recombination deficiency through various other mechanisms. Recent studies have found the class of drugs called PARP inhibitors to selectively target ovarian cancers with homologous recombination deficiency. There are eight PARP inhibitors in various phases of clinical development with four being actively studied in phase III trials in ovarian cancer. In December 2014, the first-in-human PARP inhibitor olaparib was approved for ovarian cancer patients with two different clinical indications in Europe and the United States. Summary Ovarian cancer has become a model for the successful translation of targeted therapy against DNA repair deficiencies in cancer.

引用

页码：24 / 31

页数：8

共 45 条

[1] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[2] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[3] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[4] A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J].

Coleman, Robert L. ;

Sill, Michael W. ;

Bell-McGuinn, Katherine ;

Aghajanian, Carol ;

Gray, Heidi J. ;

Tewari, Krishnansu S. ;

Rubin, Steven C. ;

Rutherford, Thomas J. ;

Chan, John K. ;

Chen, Alice ;

Swisher, Elizabeth M. .

GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :386-391

[5] DNA repair dysregulation from cancer driver to therapeutic target [J].

Curtin, Nicola J. .

NATURE REVIEWS CANCER, 2012, 12 (12) :801-817

[6]

De Bono JS, 2013, J CLIN ONCOL, V31

[7] The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art [J].

De Vos, Mike ;

Schreiber, Valerie ;

Dantzer, Francoise .

BIOCHEMICAL PHARMACOLOGY, 2012, 84 (02) :137-146

[8] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[9] Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval [J].

Fong, Peter C. ;

Yap, Timothy A. ;

Boss, David S. ;

Carden, Craig P. ;

Mergui-Roelvink, Marja ;

Gourley, Charlie ;

De Greve, Jacques ;

Lubinski, Jan ;

Shanley, Susan ;

Messiou, Christina ;

A'Hern, Roger ;

Tutt, Andrew ;

Ashworth, Alan ;

Stone, John ;

Carmichael, James ;

Schellens, Jan H. M. ;

de Bono, Johann S. ;

Kaye, Stan B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2512-2519

[10] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].

Fong, Peter C. ;

Boss, David S. ;

Yap, Timothy A. ;

Tutt, Andrew ;

Wu, Peijun ;

Mergui-Roelvink, Marja ;

Mortimer, Peter ;

Swaisland, Helen ;

Lau, Alan ;

O'Connor, Mark J. ;

Ashworth, Alan ;

Carmichael, James ;

Kaye, Stan B. ;

Schellens, Jan H. M. ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134

← 1 2 3 4 5 →